Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

Abstract Background Central nervous system (CNS) brain metastasis of advanced non-small cell lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy comparison of two first-generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib as first-...

Descrición completa

Detalles Bibliográficos

Principais autores:	Meng-Xia Li, Hao He, Zhi-Hua Ruan, Yu-Xi Zhu, Rong-Qing Li, Xiao He, Bao-Hua Lan, Zhi-Min Zhang, Guo-Dong Liu, Hua-Liang Xiao, Yan Wu, Bo Zhu, Ge Wang, Zhen-Zhou Yang
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2017-04-01
Series:	BMC Cancer
Assuntos:	EGFR-TKIs Erlotinib Gefitinib NSCLC EGFR mutation
Acceso en liña:	http://link.springer.com/article/10.1186/s12885-017-3165-0
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!